Graduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Niterói, Rio de Janeiro, Brazil.
Unidade de Pesquisa Clinica (UPC)-University Hospital Antonio Pedro, Niterói, Rio de Janeiro, Brazil.
Nutr Clin Pract. 2022 Feb;37(1):81-93. doi: 10.1002/ncp.10662. Epub 2021 May 12.
Patients with chronic kidney disease (CKD) have several pathophysiological alterations, including anemia, one of the first changes in CKD patients. More recently, researchers have observed that the intestinal microbiota alterations are also another complication in these patients. The most common treatment for anemia is oral (mainly ferrous sulfate) or intravenous iron supplementation. Despite being a necessary treatment, recent studies have reported that supplementation with oral iron may increase its availability in the intestine, leading to disturbance in the gut microbiota and also to oxidative stress in the enterocytes, which may change the permeability and the microbiota profile. Although it is a therapy routinely used in patients with CKD, supplementation with oral iron on the gut microbiota has been rarely studied in these patients. Thus, this review will discuss the relationship between iron and the gut microbiota and the possible effects of oral iron supplementation on gut microbiota in patients with CKD.
患有慢性肾病（CKD）的患者存在多种病理生理改变，包括贫血，这是 CKD 患者最早出现的改变之一。最近，研究人员观察到肠道微生物群改变也是这些患者的另一种并发症。贫血最常见的治疗方法是口服（主要是硫酸亚铁）或静脉铁补充。尽管这是一种必要的治疗方法，但最近的研究报告称，口服铁补充可能会增加其在肠道中的可用性，从而导致肠道微生物群紊乱，并导致肠细胞发生氧化应激，这可能会改变肠道的通透性和微生物群谱。虽然这是 CKD 患者常规使用的一种治疗方法，但很少有研究探讨口服铁补充对 CKD 患者肠道微生物群的影响。因此，本文将讨论铁与肠道微生物群之间的关系，以及口服铁补充对 CKD 患者肠道微生物群的可能影响。
